1 citations
,
May 2012 in “Aktuelle Urologie” This review discusses chemoprevention for prostate cancer and suggests that further open and unbiased investigation into various preventive compounds, including 5α-reductase inhibitors, is needed.
7 citations
,
January 2013 in “European Urology” This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.
44 citations
,
October 2010 in “BJUI” This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.
15 citations
,
December 2006 in “Clinical interventions in aging” This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.
August 2011 in “Der Urologe” This review discusses the impact of various treatments for prostate cancer, noting that while 5α-reductase inhibitors reduce risk, they may not decrease and could even increase high-risk cancers; the authors highlight that recent data suggest longer screening can reduce prostate cancer mortality more effectively.